Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta mRNA (PIK3CB mRNA)

The p110β mRNA is the transcript of the PIK3CB gene, which encodes the catalytic subunit of the phosphoinositide 3-kinase beta (PI3Kβ) enzyme (NCBI Gene ID: 5291). This mRNA is a critical component of the PI3K/AKT/mTOR signaling pathway, which regulates fundamental cellular processes such as growth, proliferation, and survival (UniProt P42338). A distinguishing feature of the p110β isoform is its dual activation by both receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), allowing it to integrate diverse extracellular signals (Jia et al., Nature, 2008). In oncology, p110β mRNA expression is particularly significant in PTEN-deficient cancers, such as certain prostate and breast malignancies, where the loss of the PTEN phosphatase creates a specific dependency on the p110β isoform for oncogenic signaling (Wee et al., PNAS, 2008). Beyond cancer, the p110β protein translated from this mRNA is essential for the activation of integrin αIIbβ3 in platelets, making it a key player in thrombus formation and a target for antithrombotic research (Jackson et al., Nature Medicine, 2005). While small molecule inhibitors typically target the p110β protein's kinase activity, the mRNA itself represents a target for gene-silencing technologies like siRNA and antisense oligonucleotides (ASOs) aimed at reducing the overall protein levels in diseased tissues. Targeting the mRNA provides a mechanism to bypass the challenges of kinase-domain selectivity among PI3K isoforms and offers a precision medicine approach for treating malignancies with specific genetic signatures.

Other names

p110beta mRNAPI3Kbeta mRNAPIK3CB transcriptP110-BETA mRNAPhosphoinositide 3-kinase catalytic subunit beta mRNA

Degradation of the PIK3CB mRNA transcript via the RNA-induced silencing complex (RISC) or RNase H-mediated cleavage, resulting in the knockdown of p110β protein expression and subsequent inhibition of the PI3K/AKT signaling pathway.